PCCA VersaBase® Cream

Patent-Pending Technology

An Ideal Base for All Topical Preparations

PCCA # 30-3641

Soothing and gentle, even for the most sensitive areas.

VersaBase Cream is an elegant, yet durable, topical cream. It simulates the natural moisturizing barrier of the skin through its emulsion system and rubs in quickly, leaving a soft and silky feel.

This base can be used for a variety of pharmaceutical and cosmetic applications, and is **an ideal compounding base for topical and vaginal preparations, including hormone replacement therapy**. A wide array of active ingredients can be incorporated into the base, including those used in topical, vaginal and dermatological formulations.



BENEFITS

- Noncomedogenic
- Hypoallergenic
- Nonirritating
- Odor-free
- Natural emulsifiers
- Long-lasting moisturizing effect
- Stable over a broad pH range (3.5 to 12)
- Nonionic emulsion system, compatible with cationic and anionic substances
- · No incidence of "pilling" when applied to the skin

FORMULATED WITHOUT

• Oils

- Propylene glycol
- Parabens

Petrolatum

RELATED SPECIALTIES

FXCLUSIV

- Hormone Replacement
- Women's Health
- Dermatology
- Cosmeceuticals

COMMONLY COMPOUNDED WITH

- Hormones
- Antibiotics
- Antifungals

- Corticosteroids
- Anti-aging
- Anaesthetics

Continued on the next page

USA: 800.331.2498 pccarx.com | Canada: 800.668.9453 pccarx.ca | Australia: 02.9316.1500 pccarx.com.au | UK: 0800.038.5095 pccarx.co.uk



PCCA VersaBase[®] Family

Patent-Pending Technology



THE VERSABASE FAMILY

We have developed of an entire line of topical bases, expanding your options for compounded medications to address a variety of patients' needs.

- VersaBase Cream (PCCA #30-3641): An ideal compounding base for topical and vaginal preparations, including HRT.
- VersaBase Gel (PCCA #30-3656): A compounding base for topical and vaginal preparations, including HRT. Mixes well with MucoLox[™] for an excellent vaginal formulation option.
- **VersaBase Lotion** (PCCA #30-3653): For patients who prefer a thinner topical cream.
- **VersaBase Foam** (PCCA #30-3654): An innovative foam base for topical use on the skin.
- VersaBase Shampoo (PCCA #30-4195): For all types of hair and animal fur that need pharmaceutical, cosmetic or liquid soap formulations.
- VersaBase Anhydrous HRT (PCCA #30-5056): A topical anhydrous base for female hormone delivery allowing for longer default BUDs. See PCCA Document #99737 for more details.

ALSO AVAILABLE

PCCA Special Micronized Progesterone

- Mixes well with VersaBase Cream for topical and vaginal HRT preparations.
- Particle Size: 100% <10 microns and 95-99%
 <5 microns
- Consistent source of FDA-registered facility.

PCCA #**30-3530**

FREQUENTLY ASKED QUESTIONS

Can both VersaBase Cream and VersaBase Gel be used for vaginal use?

Yes.

Can any of the VersaBase Family of bases be used orally?

No.

STUDIES

- Bassani, A.S., Banov, D., & Carvalho, M. (2017). Evaluation of the in vitro human skin percutaneous absorption of progesterone in VersBase® using the Franz skin finite dose model. Journal of women's Health Care, 6(4). https://doi.org/10.4172/2167-0420.1000384
- Glaser, R. L., Zava, D. T., & Wurtzbacher, D. (2008).
 Pilotstudy: Absorption and efficacy of multiple hormones delivered in a single cream applied to the mucous membranes of the labia and vagina. Gynecologic and Obstetric Investigation, 66(2), 111-118.
 pubmed.ncbi.nlm.nih.gov/18446040/
- Needham, S., & Needham, S. (2018). Case study: Absorption of testosterone cream via scrotal delivery. International Journal of Pharmaceutical Compounding, 22(6), 466-468.

pubmed.ncbi.nlm.nih.gov/30384346/

To learn more about these studies, visit pccarx.com/science.

PLEASE NOTE

Always make sure you have checked the PCCA formula database and are following the most up-to-date version of a formula, as changes are continually made to existing formulations to provide the highest quality. The formulas and/or statements listed are provided for educational purposes only. They are compounding ideas that have commonly been requested by physicians and have not been evaluated by the Food and Drug Administration. Formulas and/or material listed are not to be interpreted as a promise, guarantee, or claim of therapeutic efficacy or safety. The information contained herein is not intended to replace or substitute for conventional medical care or encourage its abandonment. Every patient is unique, and formulas should be adjusted to meet their individual needs.

USA: 800.331.2498 pccarx.com | Canada: 800.668.9453 pccarx.ca | Australia: 02.9316.1500 pccarx.com.au | UK: 0800.038.5095 pccarx.co.uk

